WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in three upcoming investor conferences in September 2025 as follows: Cantor Healthcare Conference: fireside chat at 8:00 am ET on Thursday, September 4th and available to host inve ...

Separately Secures Access to OneGI Through Brentwood Pharmacy Agreement Gimoti Specialty Pharmacy Network to Almost Double with Additional Relationships SOLANA BEACH, Calif. and CHICAGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI® (metoclopramide) nasal spray, together with EVERSANA, a leading provider of global commercial services to the life ...

Core Points - DFDS has entered into a mutual space charter agreement with TT Line to enhance the efficiency and scope of its Baltic Sea ferry network [1][7] - The agreement will be effective for freight on 1 October 2025 and for passengers on the Karlshamn-Klaipeda route on 1 October 2025, and on the other two routes on 1 November 2025 [2][7] - The agreement allows customers to board the next available sailing regardless of the operator, while maintaining control over commercial activities with customers [2][3] Summary by Sections Agreement Details - The space charter agreement covers the combined freight and passenger route Karlshamn-Klaipeda and grants DFDS access to TT Line routes Klaipeda-Trelleborg and Klaipeda-Travemünde [1][7] - The agreement is expected to increase sailing frequency for customers on the Karlshamn-Klaipeda route while reducing the number of sailings needed, thus helping to lower emissions [3][4] Company Overview - DFDS operates a transport network in Europe with an annual revenue of DKK 30 billion and employs 16,500 full-time staff [5] - The company was founded in 1866 and is headquartered in Copenhagen, focusing on ferry, road, and rail transport solutions [6]

LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences: Citi's 2025 Biopharma Back to School Conference: Fireside chat at 4:00 p.m. ET on Tuesday, September 2, 2025, in Boston, MA, during which the company plans to highlight preclinical data supporting its non-viral delivery platform l ...

Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating complete response (CR) Favorable safety profile observed in study participants with no dose limiting toxicities (DLTs) or immune-effector cell associated neurotoxicity syndrome (ICANS) in the dose escalation cohort Dose expansion phase of study will investigate MT-601 at pre-specified maximum dose in patients ...

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Wednesday, September 3 at 2:45-3:15 PM ET. The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archi ...

Company Overview - Balchem Corporation is a global specialty ingredient manufacturer focused on health and nutrition markets [2] - The company operates through three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products [2] Business Segments - The Human Nutrition & Health segment provides customized food and beverage ingredient systems and key nutrients for food, supplement, and pharmaceutical applications [2] - The Animal Nutrition & Health segment supplies products to various animal health markets [2] - Specialty Products segment offers specialty-packaged chemicals for healthcare and other industries, as well as chelated minerals for the micronutrient agricultural market [2] Upcoming Events - Balchem Corporation will present at the H.C. Wainwright 27 Annual Global Investment Conference on September 9, 2025, with key executives participating [1]

Core Viewpoint - Helium Evolution Incorporated (HEVI) has secured a strategic financing agreement with ENEOS Xplora Inc. for a convertible note valued at $8.3 million, increasing ENEOS Xplora's total investment in HEVI to $12.8 million, which will support HEVI's operations and growth in the helium sector [1][3]. Financing Details - The proceeds from the convertible note will fund HEVI's 20% working interest in the Soda Lake Facility and support drilling activities in the Mankota area, with operations expected to commence in Q4 2025 [2]. - The financing is set to close on August 29, 2025, and the note is convertible into common shares at a minimum price of $0.205 per share, subject to certain milestones [4][5]. Production and Royalties - HEVI has granted ENEOS USA a gross overriding royalty (GORR) on production from three designated wells tied into the Soda Lake Facility, structured on a sliding scale based on gross sales [6][9]. - The GORR includes 5% of gross sales in the first year, decreasing to 2% thereafter, which aligns with HEVI's production strategy [9]. Strategic Importance - This financing is viewed as a significant step in HEVI's growth trajectory, enhancing its financial foundation and positioning the company as a near-term helium producer [3]. - The Soda Lake Facility is considered a cornerstone project that will provide stable processing capacity and growth opportunities for shareholders [3]. Company Background - Helium Evolution is recognized as holding the largest helium land rights position in North America among publicly traded companies, with over five million acres under permit in southern Saskatchewan [14]. - The company aims to become a leading supplier of sustainably-produced helium to meet the growing global demand [14].

SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences. Cantor Global Healthcare Conference – Fireside ChatDate: Thursday, September 4, 2025Time: 1:00 p.m. - 1:30 p.m. ET ...

Core Viewpoint - Golden Heaven Group Holdings Ltd. has announced a share consolidation on a 15 for 1 ratio to regain compliance with Nasdaq listing requirements, effective August 28, 2025 [1][2]. Group 1: Share Consolidation Details - The share consolidation will automatically combine every 15 ordinary shares into one ordinary share without requiring action from shareholders [3]. - No fractional shares will be issued; shareholders will receive one full share instead of any fractional share resulting from the consolidation [3]. - The authorized share capital will remain at US$6,018,000,000 but will change the structure of Class A and Class B ordinary shares, with Class A shares decreasing from approximately 36.9 million to about 2.46 million shares, and Class B shares decreasing from approximately 1.07 million to about 71,574 shares [4]. Group 2: Company Overview - Golden Heaven operates amusement parks, water parks, and complementary recreational facilities in China, offering a variety of experiences including thrilling rides, water attractions, and entertainment events [5].